**EXPLANATORY STATEMENT**

***Private Health Insurance Act 2007***

***Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024***

**Purpose**

The purpose of the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024*(the MDHTP Rules) is to remake the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024* (the Previous Rules) to update the list of medical devices and human tissue products for which a benefit must be paid, where the listed item is provided in the conditions and circumstances specified in the *Private Health Insurance* *Act 2007* (the Act). The MDHTP Rules set out the minimum benefit payable for each listed item.

Listed items and their minimum benefits are set out in Schedule 1 to the MDHTP Rules. Schedule 1 to the MDHTP Rules is known as the list of medical devices and human tissue products (Prescribed List).

The Prescribed List has four parts:

* Part 1 - Part A – Medical Devices;
* Part 2 - Part B – Human Tissue Products;
* Part 3 - Part C – Other Medical Devices; and
* Part 4 - Part D – General Use Items (medical devices).

The MDHTP Rules also outline circumstances in which various assessments in relation to listing and variation applications are required and the associated fee for that assessment, and cost-recovery provisions, including the timing for when cost-recovery fees become due and payable, and when cost-recovery fees can be refunded, and waivers can be granted.

In line with the Australian Government Cost Recovery Policy, the MDHTP Rules have been updated to ensure they accurately reflect the efficient costs of providing services. Fees are calculated using an activity-based cost model. This ensures that the contemporary costs incurred by the Department of Health and Aged Care (the Department) when providing services relating to the assessment of applications to list or vary the Prescribed List are accurately reflected in fees. The timing of when the standard application fees for listing and variation applications is due and payable has also been updated in the MDHTP Rules to reflect that it is due and payable within 28 days from the day demand for payment of the relevant fee is made.

The MDHTP Rules differ from the Previous Rules by:

* adding 192 new listed items (billing codes) to Part A of the Prescribed List as a result of listing medical devices following successful new applications, 10 billing codes as the result of expansion applications, 2 billing codes as the result of compression applications and 222 new billing codes due to transfer of billing codes from one sponsor to another;
* changing the listing details of 127 billing codes in Part A of the Prescribed List following the successful amendment applications from the sponsors, and changes to groupings for billing codes listed incorrectly;
* deleting 415 billing codes from Part A of the Prescribed List, as a result of accepting 183 deletion applications submitted by the sponsors, removing 222 billing codes after transferring billing codes to the new sponsors, removing 4 billing codes following completion of expansion applications and removing 6 billing codes following completion of compression applications;
* adding 8 new billing codes in Part C of the Prescribed List as a result of listing medical devices following successful new applications;
* deleting 8 billing codes following acceptance of deletion applications;
* adding 60 new billing codes in Part D as a result of listing medical devices following 55 successful new applications, 2 new billing codes as the result of successful expansion applications and 3 new billing codes due to transfer of billing codes from one sponsor to another;
* Changes to 7 billing codes in Part D following the successful amendment applications; and
* deleting 32 billing codes from Part D following deletion applications and decision to remove the billing codes for medicines and accessories to medicines from the Prescribed List.

The numbers of Prescribed List billing codes were taken from reports produced by the Health Products Portal (HPP) when the list was run.

Pre-July 2024, the structure for Part A, Part C, and Part D billing codes was a two-digit alpha prefix to denote the sponsor and a three-digit number to identify the device, and for Part B billing codes were a three-digit alpha prefix to denote the sponsor and a two-digit number to identify the human tissue product. Due to the number of sponsors of medical devices listed on the PL, the number of two-digit alpha prefixes has been exhausted. From 1 July 2024 all new billing codes are presented as a six-digit number only and are allocated to the new billing codes sequentially.

In addition to the new and amended billing codes change, the MDHTP Rules also differ from the Previous Rules by correcting the listing details of billing codes that were identified as being listed in incorrect groupings (meaning category-subcategory-group-subgroup-suffix); that is, the devices do not have the attributes to fit in the groupings, they are currently listed in.

When Prescribed List billing codes are transferred from one sponsor to a different sponsor, or billing codes are compressed or expanded following the respective application, the Prescribed List billing codes that are transferred, expanded, or compressed are deleted.

The MDHTP Rules also differ from the Previous Rules by omitting the provision that defined ‘medical device’, which widened the scope of the meaning set out at paragraph 72-11(1)(b) of the Act.

Section 11 of the MDHTP Rules, which sets out the general listing criteria, has also been updated to provide that a medical device or human tissue product must not be listed in the Prescribed List unless it is included as a medical device or biological in the Australian Register of Therapeutic Goods maintained under section 9A of the *Therapeutic Goods Act 1989*.

**Background**

The Table in subsection 72-1(2) of Part 3-3 of the Act (Table) provides for benefit requirements a complying health insurance policy that covers hospital treatment must meet. Under item 4 of the Table, there must be a benefit for the provision of a medical device or human tissue product, of a kind listed in the MDHTP Rules, in specified circumstances and under any specified conditions. The specified circumstances are that the listed item is provided in circumstances in which a medicare benefit is payable or in other circumstances which may be set out in the MDHTP Rules. The specified conditions are any that may be set out in the MDHTP Rules.

If the complying health insurance policy also covers hospital-substitute treatment then under item 4 of the Table, the same requirements apply.

Subsection 72-10(2) of the Act provides that a person may apply to the Minister to have the MDHTP Rules list a medical device or human tissue product of the kind to which the application relates to (listed item). The applicant for these applications is known as the ‘applicant’ and for a listed item, the ‘sponsor’ is the person who made the listing application as a result of which the device or product was listed.

**Authority**

Item 4 of the Table in section 333-20 of the Act provides that the Minister may make the MDHTP Rules, providing for matters required or permitted by Part 3-3 of the Act, or necessary or convenient in order to carry out or give effect to Part 3-3 of the Act.

Subsection 72-10(5) of the Act applies if the Minister grants the application and the applicant pays any cost-recovery fee that the applicant is liable to pay in relation to the initial listing of the kind of medical device or human tissue product to which the application relates. If the Minister grants the application and the applicant pays the cost-recovery fee then the Minister must list the kind of medical device or human tissue product the next time the Minister makes or varies the MDHTP Rules.

Subsection 72-10(6) of the Act provides that the MDHTP Rules may set out criteria that must be satisfied in order for an application to be granted.

Section 72-15 of the Act provides for the MDHTP Rules to specify cost-recovery fees for activities carried out by, or on behalf of, the Commonwealth in connection with the performance of functions, or the exercise of powers, conferred by or under the Act in relation to the listing of kinds of medical devices and human tissue products in the MDHTP Rules.

**Reliance on subsection 33(3) of the *Acts Interpretation Act 1901***

In addition to the power to make this instrument under section 333-20 of the Act, subsection 33(3) of the *Acts Interpretation Act 1901* provides that where an Act confers a power to make, grant or issue any instrument of a legislative or administrative character (including rules, regulations or by-laws), the power shall be construed as including a power exercisable in the like manner and subject to the like conditions (if any) to repeal, rescind, revoke, amend, or vary any such instrument.

**Commencement**

The MDHTP Rules commence on 1 November 2024.

**Consultation**

The rule-maker had regard to recommendations made by the Prostheses List Advisory Committee (PLAC) and the Medical Device and Human Tissue Advisory Committee (MDHTAC) (whichever committee was in place at the time of assessing the applications). The PLAC and MDHTAC took into consideration advice provided by clinicians with appropriate knowledge and expertise in the (then) Clinical Advisory Groups, (then) Panel of Clinical Exerts, and Expert Clinical Advisory Groups, and advice provided by the Medical Services Advisory Committee where required.

Applicants who applied under subsection 72-10(2) of the Act for the listing of medical devices or human tissue products in the MDHTP Rules or amending the existing billing codes for listed items had opportunities to provide further information and clarification regarding their devices and products during assessment of their applications.

Further, updates to the MDHTP Rules have been made following consultation with medical devices and human tissue product stakeholders affected by the changes occurred in relation to the updates to the cost-recovery fees via the draft 2024-25 Cost Recovery Implementation Statement.

*Prescribed List reforms*

The Prescribed List and its arrangements have been subject to the reforms announced in the 2021-22 Budget, building on the previous reform activities. These reforms are being implemented over a number of years with transitional arrangements.

The aim of these reforms includes improving sustainability of private health insurance and measures including better aligning the Prescribed List benefits with the prices paid in the public hospital system.

**General**

The MDHTP Rules are a legislative instrument for the purposes of the *Legislation Act 2003*.

Details of the MDHTP Rules are set out in **Attachment A.**

This instrument is compatible with the human rights and freedoms recognised or declared under section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*. A full statement of compatibility is set out in **Attachment B**.

**ATTACHMENT A**

**Details of the *Private* *Health Insurance (Medical Devices and Human Tissue Products) Rules***

***(No. 2) 2024***

**Part 1 ­ Preliminary**

**Section 1 ­ Name**

Section 1 provides that the name of the instrument is the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024.*

**Section 2 ­ Commencement**

Section 2 provides that the instrument commences on 1 November 2024.

**Section 3 ­ Authority**

Section 3 provides that the instrument is made under item 4 of the Table in section 333‑20 of the *Private Health Insurance Act 2007*.

**Section 4 ­ Definitions**

Section 4 defines certain terms used in the instrument, and notes that some expressions used in the instrument have the same meaning as in the Act.

The following definitions in section 4 incorporate legislative instruments as in force from time to time. These instruments can be accessed free of charge on the Federal Register of Legislation at www.legislation.gov.au.

* ‘active implantable medical device’ and ‘implantable medical device’ have the same meaning as in the *Therapeutic Goods (Medical Devices) Regulations 2022*;
* ‘certified overnight Type C procedure’ and ‘certified Type C procedure’ have the same meaning as in the *Private Health Insurance (Benefit Requirements) Rules 2011*;
* ‘professional attendance’ has the same meaning as in clause 1.2.5 of Schedule 1 to the *Health Insurance (General Medical Services Table) Regulations 2021*;
* ‘registered podiatric surgeon’ means a podiatric surgeon who holds specialist registration in the specialty of podiatric surgery under National Law. The note to this definition provides that the registration requirements for a registered podiatrist for the purpose of the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024* (MDHTP Rules) are the same as the requirements set out in rule 8 of the *Private Health Insurance (Accreditation) Rules 2011.*

Section 4 also includes a new definition of a ‘former Prescribed List’ which is the Schedule to the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024* (as in force before that instrument was repealed). This can be accessed free of charge from the Federal Register of Legislation.

Section 4 also includes a definition of ‘National Law’ which refers to state and territory legislation that regulates health practitioners. The definition defines the National Law on the basis of the legislation in force at the commencement of the MDHTP Rules (not as amended from time to time). The National Law is freely available on state and territory legislation registers.

Section 4 includes a definition of a ‘listed item’ to refer to the kinds of medical devices and human tissue products that are listed in Schedule 1 of the MDHTP Rules. The list of medical devices and human tissue products in Schedule 1 is known as the listed medical devices and human tissue products (Prescribed List).

Section 4 also includes a definition of ‘specified listed item’ to refer to those particular listed items, for which the method for calculating specified benefits are outlined in section 8. This definition has been updated to remove references to a vascular drug eluting balloon catheter, a coronary drug eluting balloon catheter and a radiofrequency delivery device for transurethral water vapour ablation, as these devices are not ablation devices for the purposes of section 8.

**Part 2 ­ Benefit requirements for private health insurance policies that cover hospital treatment and hospital-substitute treatment**

**Section 5 ­ Listing of medical devices and human tissue products**

The Table in subsection 72-1(2) of the Act (the Table) sets out requirements a policy that covers hospital treatment must meet in order for the policy to be a complying health insurance policy under section 63-10 of the Act. Item 4 of the Table provides that there must be a benefit for hospital treatment covered under the policy and hospital-substitute treatment, where the policy also covers hospital-substitute treatment. The benefit applies for hospital treatment or hospital-substitute treatment that involves the provision of a listed item:

* in the circumstances in which a medicare benefit is payable or those other circumstances set out in the MDHTP Rules; and
* when the conditions set out in the MDHTP Rules, if any, are also satisfied. If the conditions are not satisfied, there is no benefit required even if the listed item is provided in the circumstances as set out either under the Act or the MDHTP Rules.

Section 5 specifies the list of medical devices and human tissue products for the purposes of item 4 of the Table. Section 5 provides that the Prescribed List sets out these listed items.

The first note under Section 5 provides that if the Minister grants a listing application and the listing fee is paid within the required timeframe, the instrument must list the medical device or human tissue product to which the application relates and must set out the minimum benefit for the device or product, and if considered appropriate, set out the maximum benefit for the device or product.

The second note under Section 5 provides that if an applicable cost-recovery fee is not paid for the application to list a medical device or human tissue product, then that medical device or human tissue product may be removed from the Prescribed List.

**Section 6 ­ Circumstances in which listed items are provided—other than circumstances in which a medicare benefit is payable**

Section 6 specifies circumstances for the purposes of paragraph (d) of the column headed “There must be a benefit for…” in item 4 of the Table in subsection 72-1(2) of the Act. A benefit must be payable under a complying health insurance policy for covered hospital treatment and hospital-substitute treatment (if the policy covers hospital-substitute treatment) for provision of a listed item that is associated with podiatric treatment by a registered podiatric surgeon. This is the case even if a medicare benefit is not payable for the provision of that listed item.

The note in section 6 provides that the provision of a listed item in circumstances in which a medicare benefit is payable is dealt with in paragraph (c) of the column headed “There must be a benefit for…” in item 4 of the Table in subsection 72(1)(2) of the Act.

**Section 7 ­ Conditions to be satisfied in relation to the provision of listed items**

Section 7 specifies conditions that must be satisfied in relation to the provision of a listed item. Under paragraphs (c) and (d) of the column headed “There must be a benefit for…” in item 4 in the Table in subsection 72-1(2) of the Act, the MDHTP Rules may set out conditions that must be satisfied in relation to the provision of a listed item in circumstances in which a medicare benefit is payable, or in the circumstances set out in section 7. If these conditions are not satisfied, no benefit is payable under a complying health insurance policy that covers hospital treatment or hospital-substitute treatment.

Subsection 7(2) provides that the conditions that must be satisfied in the case of a listed item are those conditions specified (if any) under the heading ‘Condition’ for that listed item in the Prescribed List. There are 114 billing codes listed in the Prescribed List which have a condition.

If the listed item is for an insulin infusion pump, in addition to any statement of requirement which is set out in the Schedule, the professional service associated with providing the insulin infusion pump to the patient must be:

1. a professional attendance by a consultant physician in the practice of the consultant physician’s specialty;
2. be provided as a certified Type C procedure or a certified overnight Type C procedure;
3. provided for the purpose of administering insulin.

The note in section 8 provides that item 4 of the table sets out other requirements in relation to benefits for the provision of listed items that a policy that covers hospital treatment must meet. These requirements relate to benefits for hospital treatment and, if the policy covers hospital substitute treatment, to the benefits of that coverage as well.

The listed items and billing codes with conditions include:

Part A

BF025 *(Pedicle Screw)*

BF026 *(Pedicle Screw)*

BF027 *(Locking Element)*

BF028 *(Rods, Curved)*

BF029 *(Rods)*

BF031 *(MixMax Bone Cement)*

CR032 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament)*

CR201 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament - AC30RA )*

CR202 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament – LAC 20)*

CR203 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament - LAC 30)*

CR204 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament - MCL 32)*

CR205 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament - Rotator Cuff CR 25)*

CR206 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament - Rotator Cuff CR 30)*

CR214 *(Ligament Advanced Reinforcement System (LARS) Artificial Ligament)*

DE669 *(icotec Pedicle System Polyaxial Screw)*

DE670 *(icotec Pedicle System Rod)*

DE671 *(icotec Pedicle System Set Screw)*

DE678 *(icotec Anterior Cervical Plate System - Screw)*

DE679 *(icotec Anterior Cervical Plate)*

DE680 *(icotec Anterior Cervical Plate)*

DE818 *(BlackArmor Carbon Fibre/PEEK Curved / Multicurved Rods)*

HI001 *(DDN Guide)*

HI002 *(DDN Biomodel)*

HI005 *(DDN Biomodel)*

HI006 *(DDN Guide)*

HU267 *( Cerclage System)*

HW544 *(Stryker Anatomical Biomodel for Mandible)*

HW546 *(Stryker Anatomical Biomodel for PEEK)*

HW650 *(VSP Orthognathics Bundle (Surgical Guide and Implants))*

HW651 *(VSP Orthognathics Bundle (Custom Biomodel and Implants))*

HW652 *(VSP Reconstruction Maxillofacial Case Bundle)*

HW653 *(VSP Reconstruction Mandibular/Maxillary Case Bundle)*

HW678 *(Monterey AL, Cage with integral fixation )*

HW776 *(Cayman United Plate)*

HW785 *(AutoPlex Mixer and Delivery System with VertaPlex HV)*

HW856 *(Augment Bone Graft - rhPDGF-BB component)*

IJ022 *(Regenerative Dural Repair Patch (ReDuraTM))*

IJ023 *(Regenerative Dural Repair Patch (ReDuraTM))*

IJ024 *(Regenerative Dural Repair Patch (ReDuraTM))*

IJ025 *(Regenerative Dural Repair Patch (ReDuraTM))*

KN004 *(Invictus Spinal Cement System )*

KT004 *(UNIQOS Patient Specific Anatomical Biomodel)*

KT005 *(UNIQOS Patient Specific Surgical guides)*

LB088 *(CREO Stabilization System Locking Cap)*

LB089 *(CREO Stabilization System Preassembled Monoaxial Screw)*

LB181 *(REFLECT Staple)*

LH722 *(TissuePatchDural 100\*100)*

LH765 *(Neodura Dural Repair Patch ≤10cm²)*

MA545 *(Ligamys DIS Suture with button)*

MI402 *(Cobalt™ XT DR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI403 *(Cobalt™ DR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI404 *(Crome™ DR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI405 *(Cobalt™ XT DR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI406 *(Cobalt™ DR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI407 *(Cobalt™ XT VR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI408 *(Cobalt™ VR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI409 *(Crome™ VR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI410 *(Cobalt™ XT VR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI411 *(Cobalt™ VR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI412 *(Crome™ VR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI413 *(Crome™ DR ICD MRI SureScan™ with BlueSync mobile remote monitoring)*

MI416 *(Cobalt™ HF Quad CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI417 *(Cobalt™ HF CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI418 *(Crome™ HF Quad CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI419 *(Crome™ HF CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI420 *(Cobalt™ XT HF Quad CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI421 *(Cobalt™ XT HF CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI422 *(Crome™ HF Quad CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI423 *(Crome™ HF CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI424 *(Cobalt™ XT HF Quad CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI425 *(Cobalt™ XT HF CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI426 *(Cobalt™ HF Quad CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI427 *(Cobalt™ HF CRT-D MRI SureScan™ with BlueSync mobile remote monitoring)*

MI439 *(Percepta Quad MRI SureScan CRT-P with BlueSync mobile remote monitoring)*

MI440 *(Percepta MRI SureScan CRT-P with BlueSync mobile remote monitoring)*

MI441 *(Serena Quad MRI SureScan CRT-P with BlueSync mobile remote monitoring)*

MI442 *(Serena MRI SureScan CRT-P with BlueSync mobile remote monitoring)*

MI446 *(Azure XT SR MRI SureScan with BlueSync mobile remote monitoring)*

MI447 *(Azure S SR MRI SureScanTM with BlueSync mobile remote monitoring)*

MI448 *(Azure XT DR MRI SureScan with BlueSync mobile remote monitoring)*

MI449 *(Azure S DR MRI SureScan with BlueSync mobile remote monitoring)*

MV007 *(MGuide)*

OG001 *(OMX Solutions patient Optimized Guide system)*

OG004 *(The OMX Solutions Biomodel)*

QQ001 *(Anatomics Biomodel)*

QQ008 *(Anatomics Patient Specifc Surgical Guide)*

QQ013 *(Anatomics Patient Specific Surgical Guide)*

QQ014 *(Anatomics Surgical Guide)*

QQ199 *(NEUTRINO NxT VR ICD Model CDVRA600Q)*

QQ200 *(Neutrino NxT DR ICD Model CDDRA600Q)*

QQ164 *(Neutrino NxT HF CRT-D Model CDHFA600Q)*

QQ311 *(Stryker Patient-Matched TMJ – Anatomic Biomodel)*

QQ312 *(AI Guide)*

SJ417 *(Gallant VR ICD Model CDVRA500Q)*

SJ418 *(Gallant DR ICD Model CDDRA500Q)*

SJ424 *(Gallant HF CRT-D Model CDHFA500Q)*

SJ482 *(Navitor™ Transcatheter Aortic Valve)*

SK494 *(DuraMatrix)*

SY777 *(ProPlan)*

SY778 *(ProPlan)*

SY779 *(ProPlan)*

SY829 *(Custom made plates (including Megaplates) – Surgical Guides)*

SY830 *(Surgical Guide for OBL PorousiTi® PSI System – Orbital Floor)*

UI001 *(OsGuide)*

UI002 *(BIOMODEL)*

UI003 *(DGUIDE)*

UI004 *(OMF Model)*

ZZ046 *(OrthoTin Anatomic Biomodel)*

ZZ047 *(OrthoTin Surgical Guide)*

ZZ049 *(Lyka Smith Patient Specific Guides)*

ZZ050 *(Lyka-Smith Anatomical Biomodel)*

Part C

BS416 (*Rezum)*

II001 (*Omnipod DASH® Insulin Management System - Personal Diabetes Manager (PDM) & Software only)*

QQ717 *(Omnipod 5 Automated Insulin Delivery System)*

The specific conditions for these 114 codes are below.

Part A

* QQ001, QQ008, QQ013, QQ014, QQ311, QQ312, HI001, HI002, HI005, HI006, HW544, HW546, HW650, HW651, HW652, HW653, KT004, KT005, MV007, OG001, OG004, SY777, SY778, SY779, SY829, SY830, UI001, UI002, UI003, UI004, ZZ046, ZZ047, ZZ049 and ZZ050 - Prescribed List reimbursement is restricted to the use of the device in craniomaxillofacial surgery procedures involving insertion of an implantable medical device, where that implantable device is listed in either sub-category 07.01 - Craniomaxillofacial Reconstruction & Fixation, or 07.02 – Craniomaxillofacial Implants, or 07.04 – Distractor Systems of Schedule 1, or sub-category 07.03 - Dental Implants, but only if the implantable medical device is explicitly identified in the product name or description of the billing code for the surgical guide or biomodel and is used in hospital. Not limiting the above, for a claim for any implantation procedure (defined by the respective MBS items stated in the claim) for a patient, the Prescribed List reimbursement is limited to 3 or less PL benefits for any billing codes for surgical guides or biomodels, or no more than 6 benefits if both surgical guides and biomodels (maximum 3 for each) have been used in an implantation procedure for a patient. This restriction is not impacted by a number of devices implanted during a procedure. The condition is taking effect on 1 February 2024. ;
* CR032, CR201, CR202, CR203, CR204, CR205, CR206, CR214, and MA545 – that an Artificial Ligament should only be funded for intra-articular cases where no non-synthetic graft sources (allografts and autografts) are available;
* HU267 – only to be reimbursed when used in a surgical procedure described in item 47450, 47528 or 47565 in Group T8 of the Regulations;
* BF025, BF026, BF027, BF028, BF029, DE669, DE670, DE671, DE678, DE679, DE680 and, DE818 – Only to be reimbursed when used in patients with spinal tumours requiring regular magnetic resonance imaging (MRI) and/or computerised tomography (CT) imaging and or adjuvant radiotherapy and/or proton therapy;
* HW678 – this billing code is for Monterey AL Cage but only when it is used with screws to achieve integral fixation. It was noted that when the cage is used without screws it should be listed on Prescribed List in the grouping 13.10.02.02 Spinal, Fusion cage, interbody, no integral fixation, ThoracoLumbar/Lumbar;
* HW776 – to be reimbursed only when used with posterior supplemental fixation with other implants;
* BF031, HW785 and KN004 - No PL benefit will be payable if the device is used for kyphoplasty surgery, as there is no MBS item available for this procedure*;*
* HW856 - The Prescribed List benefit is limited to reimbursement for the use of the device as an alternative to autograft in hindfoot and ankle fusion procedures that require supplemental graft material, including tibiotalar, tibiocalcaneal, talonavicular and calcaneocuboid fusions, or any other procedure if stated in the Intended Purpose in the Australian Register of Therapeutic Goods (ARTG) entry 191454;
* IJ022, IJ023, IJ024, IJ025, LH722, LH765, and SK494 - The Prescribed List benefit will be limited to use of the device for procedures related to dura defect repair in spinal and neurosurgical procedures.);
* LB088, LB089 and LB181 - The Prescribed List billing code does not cover the use of the device for vertebral body tethering (VBT) for the management of adolescent idiopathic scoliosis (AIS);
* 100164, 100199, 100200, MI402, MI403, MI404, MI405, MI406, MI407, MI408, MI409, MI410, MI411, MI412, MI413, MI416, MI417, MI418, MI419, MI420, MI421, MI422, MI423, MI424, MI425, MI426, MI427, MI439, MI440, MI441, MI442, MI446, MI447, MI448, MI449, SJ417, SJ418, and SJ424 – The benefit includes a component for remote monitoring services provided via a remote monitoring system or a smart device application. A separate benefit cannot be claimed in respect of a remote monitoring system listed on Part C of the Schedule;
* SJ482 - The listed item covers the Navitor System, containing Transcatheter Aortic Valve (cat. numbers NVTR-23, NVTR-25, NVTR-27, NVTR-29), FlexNav™ Delivery System (cat. numbers FNAV-DS-SM, FNAV-DS-LG) and Loading System (NVTR-LS-SM and NVTR-LS-LG), and the benefit is payable for the listed item if the Navitor System is used for the surgical procedure described in item 38495 in Group T8 of the Regulations;

Part C

* BS412 - Private health insurers are not required to pay benefits in respect of this billing code until 1 March 2024 when a Medicare benefit will be payable for the service.
* II001 and
* QQ717 - The benefit for the device is payable no more frequently than once every 4 years.

**8 ­ Benefits for listed items provided as part of hospital treatment**

Section 8 provides for the minimum benefits paid for listed items provided as part of hospital treatment. Subsection 8(1) provides that this section is made for the purposes of paragraph (a) of the column headed “The amount of the benefit must be…” in item 4 of the Table in subsection 72-1(2) of the Act, which provides that the minimum benefit is the amount that is set out, or worked out, in the MDHTP Rules.

Subsection 8(2) provides that the minimum benefit for a listed item (other than specified listed item) that is provided to a private patient in a private hospital is the amount specified in the column headed “Minimum benefit” of the Table in the Prescribed List for that listed item.

Subsection 8(3) provides that the method for calculating the minimum benefit for a specified listed item for a private patient in a private hospital is outlined in subsection 8(6). These specified listed items are defined in section 5 of the MDHTP Rules.

In relation to treatment provided in a public hospital, subsection 8(4) specifies the method for calculating the minimum benefit amount for a listed item (other than specified listed item), and subsection 8(5) specifies the method for calculating the minimum benefit amount for a specified listed item.

The provision of listed items and specified listed items in public hospitals are subject to different arrangements that reflect the public hospital procurement activities and therefore the cost for a specified listed item in a public hospital may be lower than in a private hospital. To reflect this, subsections 8(4) and 8(5) provide for a lower payable benefit for a listed item or a specified listed item that is consistent with the insured person’s liability to the public hospital for the provision of that listed item or specified listed item. This only applies if the listed item or specified listed item is provided in a public hospital for an amount that is lower than the amount specified for that listed item or specified listed item in the Prescribed List.

Subsection 8(6) provides the method for the minimum benefit amount for a specified listed item. The method is described as:

1. if the sum of the default minimum benefits for the treatment in which the specified listed item was used is $6,399 or less, the minimum benefit is the default minimum benefit for the listed item; or
2. if the sum of the default minimum benefits for the procedure treatment in which the specified listed item was used is more than $6,399, the benefit is worked out by dividing the default minimum benefit for the specified listed item by the sum of the default minimum benefits for the treatment in which the specified listed item was used and multiplying the result by $6,399.

The note under subsection 8(6) provides an example of calculating the minimum benefit for the purpose of paragraph 8(6)(b). The example states that if an irrigated cardiac ablation catheter, a mapping catheter for catheter cardiac ablation and a patch for cardiac ablation are each listed in the Prescribed List and are used in a relevant procedure in accordance with any conditions, and if:

1. the default minimum benefit of the irrigated cardiac ablation catheter is X; and
2. the default minimum benefit of the mapping catheter for cardiac ablation is Y; and
3. the default minimum benefit of the patch for cardiac ablation is Z;

then the sum of the default minimum benefits for the procedure is (X+Y+Z). If the sum of the default minimum benefits for the procedure (X+Y+Z) is more than $6,399, the minimum benefit for the irrigated cardiac ablation catheter is calculated by taking X, dividing it by (X+Y+Z), then multiplying the result by $6,399.

Subsection 8(7) defines the meaning of ‘default minimum benefit’ and ‘sum of default minimum benefits’ for the purposes of section 8.

**Section 9 ­ Benefits for listed items provided as part of hospital-substitute treatment**

Section 9 provides for the minimum benefits paid for listed items provided as part of hospital-substitute treatment. Subsection 9(1) provides that this section is made for the purposes of paragraph (a) of the column headed “The amount of the benefit must be…” in item 4 of the Table in subsection 72-1(2) of the Act, which provides that the minimum benefit is the amount that is set out, or worked out, in the MDHTP Rules.

Subsection 9(2) provides that, for a listed item provided as part of an episode of hospital-substitute treatment, the minimum benefit is the amount specified in the column headed “Minimum benefit” in the Prescribed List for that listed item.

The note under section 9 states that as part of hospital-substitute treatment, private health insurers cannot cover a service for which a medicare benefit is payable unless the service is specified in the Private Health Insurance (Health Insurance Business) Rules.

**Part 3 ­ Listing criteria**

**Section 10 ­ Purpose**

Section 10 explains the purpose of Part 3 which sets out the listing criteria.

Subsection 72-10(6) of the Act provides that the MDHTP Rules may set out listing criteria that must be satisfied in order for an application to be granted. The listing criteria operate with all the provisions in the Act, including the definitions of ‘medical device’ and ‘human tissue product’.

Subsection 72-10(7) of the Act provides that the Minister must not grant a listing application if any applicable listing criteria are not satisfied in relation to the application. The Minister may refuse to grant a listing application even if the listing criteria are satisfied.

**Section 11 ­ General listing criteria**

Section 11 provides that a medical device or human tissue product must not be listed in the Prescribed List unless it is included as a medical device or biological in the Australian Register of Therapeutic Goods maintained under section 9A of the *Therapeutic Goods Act 1989*. This is to ensure that the Department can independently verify that the medical device or biological may be legally supplied in Australia.

**Section 12 ­ Listing criteria for medical devices to be listed in Part A of Schedule 1**

Section 12 provides listing criteria for medical devices which are to be listed in Part A of the Prescribed List. This criterion reflects what has historically been applied administratively when assessing applications for listing medical devices in the MDHTP Rules (or its predecessor).

Subsection 12(1) provides that a medical device must not be listed in Part A of the Prescribed List unless the criteria in subsections 12(2) to 12(5) are satisfied.

Subsection 12(2) specifies conditions that must be met for a medical device to be listed in Part A of the Prescribed List. Paragraph 12(2)(a) provides that the medical device must be an implantable medical device, or an active implantable medical device designed to either replace an anatomical body part, or combat a pathological process, or modulate a physiological process. Reference in relation to a ‘modulating a physiological process’ can include blocking or facilitating a process.

Subsection 12(2) is also for associated products that are essential and specifically designed to enable the implantation (outlined in paragraph 12(2)(b)) or maintaining the implant (outlined in paragraph 12(2)(c)) of this subsection.

To meet these criteria, the device must be specifically designed as an integral single-use aid and be essential for implanting a device mentioned in paragraph 12(2)(a), or be critical to the continuing function of an implanted device mentioned in paragraph 12(2)(a), and only be suitable for use post-implantation by the patient in whom the device in subsection 12(2)(a) is implanted.

Single-use aid means a device that is intended to be used on one individual during a single procedure, and once it is used, the device cannot be used again and may only be discarded, and the expression ‘integral’ has its common meaning (i.e. not defined).

The note following subsection 12(2) clarifies that these criteria effectively mean that there is a device in paragraph 12(2)(a) (with which the device in (b) or (c) is designed to be used with) that is a listed item or will be a listed item following a successful listing application or variation application. The non-implantable devices do not meet the criteria for listing if such connection in the design does not exist.

Subsection 12(3) provides that the medical device for listing in Part A of the Prescribed List must not be designed to be solely used for diagnosis, prediction or prognosis.

Subsection 12(4) provides that the medical device for listing in Part A of the Prescribed List must be for a specific treatment and indication. This means that the medical device is specifically designed to deliver the main treatment or be part of the main treatment rather than be designed to be supplementary to the main treatment or provide general support during a variety of different procedures.

The purpose of this criterion is to reflect the current administrative practice and exclude medical devices that are listed in Part D from inclusion in Part A of the Prescribed List.

Subsection 12(5) provides that a medical device for listing in Part A of the Prescribed List must be assessed to be no less clinically effective than the alternative devices listed in the Prescribed List or the alternative treatments; and the benefit amount for the medical device must be proportionate to the clinical effectiveness of the device.

This criterion reflects what is currently applied administratively for including items in the MDHTP Rules (or its predecessor). This criterion is included with the intention that comparative clinical effectiveness and relative cost be considered.

The term ‘alternative treatments’ is included to allow for new products or technology to be compared with current treatments for the same clinical condition, as not all products to be considered have an existing comparator on the Prescribed List. The alternative treatment is generally expected to be the current standard of care for the condition or indication.

The wording ‘no less clinically effective’ is used because products are rarely identical and a range of factors may need to be balanced against each other when comparing clinical effectiveness.

A product’s cost should be compared to alternative treatments and considered in relation to its clinical benefits.

**Section 13 ­ Listing criteria for human tissue products to be listed in Part B of Schedule 1**

Section 13 provides that only human tissue products may be listed in Part B of the Prescribed List. This is consistent with what is currently applied administratively for including items in the MDHTP Rules (or its predecessor).

The note under this section refers the reader to section 72-12 of the Act, which defines ‘a human tissue product’.

**Section 14 ­ Listing criteria for medical devices to be listed in Part C of Schedule 1**

Section 14 provides listing criteria for medical devices which are to be listed in Part C of the Prescribed List.

Subsection 14(1) provides that a medical device must not be listed in Part C of the Prescribed List unless subsections 14(2) and 14(3) are satisfied.

Subsection 14(2) specifies the list of existing groups of medical devices that are currently eligible to be listed in Part C of the Prescribed List. Unless a medical device is one of these items, it is not eligible to be listed.

The note under this subsection provides that the MDHTP Rules may be varied from time to time to add additional devices to, or remove devices from, this subsection.

Subsection 14(3) provides that a medical device must be assessed to be no less clinically effective than the alternative devices listed in the Prescribed List or the alternative treatments and the benefit amount for the medical device must be proportionate to the clinical effectiveness of the device.

This criterion is included with the intention that comparative clinical effectiveness and relative cost be considered for including items in Part C of the Prescribed List.

The term ‘alternative treatments’ is included to allow for new products or technology to be compared with current treatments for the same clinical condition, as not all products to be considered have an existing comparator on the Prescribed List. The alternative treatment is generally expected to be the current standard of care for the condition or indication.

**Section 15 ­ Listing criteria for medical devices to be listed in Part D of Schedule 1**

Section 15 provides listing criteria for medical devices which are to be listed in Part D of the Prescribed List.

Subsection 15(1) provides that a medical device must not be listed in Part D of the Prescribed List unless subsections 15(2), 15(3) and 15(4) are satisfied.

Subsection 15(2) specifies that for a new Part D listing, the listing or variation application relating to the medical device must request listing in one of the categories, subcategories, groups, subgroups or suffixes that is already specified in Part D of the former Prescribed List. This is regardless of whether the billing code for the medical device has changed.

The note under subsection 15(2) clarifies that the Prescribed List groups medical devices according to their similarity in characteristics, functionality and clinical effectiveness. These groupings in the Prescribed List include categories, subcategories, groups, subgroups and suffixes. Any new or variation listings for Part D can only be listed in a category, subcategory, group, subgroup or suffix that already exists in the former Prescribed List. This means that new listing or variation applications cannot seek to establish a new category, subcategory, group, subgroup or suffix for Part D of the Prescribed List.

The former Prescribed List, which is the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024,* is publicly available on the Federal Register of Legislation at www.legislation.gov.au.

Subsection 15(3) provides that the medical device must be comparable to a listed item in Part D of the Prescribed List.

Subsection 15(4) provides that a medical device must be assessed to be no less clinically effective than the alternative devices listed in the Prescribed List, and that the comparison must demonstrate that the benefit amount for the medical device must be proportionate to the clinical effectiveness of the device.

This criterion is included with the intention that comparative clinical effectiveness and relative cost be considered for including items in Part D of the Prescribed List.

**Part 4 ­ Cost-recovery fees**

**Division 1 – Cost-recovery fees relating to medical devices**

**Section 16 ­ Cost-recovery fees that may be charged**

Section 16 outlines cost-recovery fees that may be charged for the purposes of section 72-15 of the Act. Subsection 16(1) outlines that cost-recovery fees will be charged for the activities undertaken to consider listing or variation applications relating to a medical device on the Prescribed List. Cost-recovery fees will not apply to listing or variation applications relating to human tissue products in Part B of the Prescribed List.

This fee is charged by the Department to recover the cost of providing services in response to applications to list or vary a medical device on the Prescribed List. Fees have been determined via an activity-based charging model following a review of all costs associated with the administration of the Prescribed List.

Subsection 16(2) specifies a standard application fee of $1,420 and any additional fees that will be applied according to the level and type of assessment (assessment pathway) required. This fee has been updated from the previous standard application fee of $1,370 which were specified in the Previous Rules.

The standard application fee recovers the costs associated with the initial departmental assessment of eligibility of the medical device for listing, correctness of the grouping, and appropriateness of the information the sponsor has provided in the application. The standard application fee is charged per medical device.

The additional fees include a clinical assessment fee if a clinical assessment is required, an economic assessment fee if an economic assessment is required, and a full health technology assessment pathway fee if a full health technology assessment is required.

**Section 17 ­ Clinical assessment fee**

Section 17 outlines circumstances in which a clinical assessment is required and the fee for that assessment. Paragraph 72-15(2)(c) of the Act enables the MDHTP Rules to specify the circumstances in which a cost-recovery fee is charged.

Subsection 17(1) prescribes when a clinical assessment is required for a listing or variation application relating to medical devices. All assessments include consideration on whether the devices in the applications are no less clinically effective than other devices listed on the Prescribed List or the alternative treatments, and whether the benefits stated in the applications (or for the billing codes in case of variation applications) are proportionate (correct, appropriate) in context of the clinical effectiveness of the devices.

A clinical assessment is required in circumstances where expert clinical advice from a clinical expert with relevant expertise is necessary to determine whether the medical device satisfies the listing criteria for Parts A, C and D, or, under subsection 17(1)(b), where the Minister is satisfied on “any other grounds” that the application for a listing or variation requires a clinical assessment.

Examples of “any other grounds” that may satisfy the Minister or delegate that an application requires a clinical assessment are:

* if the sponsor submits a variation application, or
* if the sponsor resubmits an application, which was assessed at the time of the initial assessment and compliance with the listing criteria was established, but expert clinical advice is required to determine whether ARTG entry and/or MBS items stated in the application are correct.

The first note under subsection 17(1) clarifies that the listing criteria for Parts A or C of the Prescribed List referred to in paragraph 17(1)(a) relate to whether the medical device was compared to medical devices listed in the Prescribed List or alternative treatments, and the medical device is no less clinical effective than alternative devices or treatments and the benefit amount is proportionate to the clinical effectiveness of the device.

The second note under subsection 17(1) clarifies that the listing criteria for Part D of the Prescribed List referred to in paragraph 17(1)(a) relate to whether the medical device was compared to medical devices listed in the Prescribed List, and the medical device is no less clinical effective than alternative devices and the benefit amount is proportionate to the clinical effectiveness of the device.

The third note under subsection 17(1) draws to readers’ attention that where the Minister (including a delegate) is satisfied that the application requires a clinical assessment, notice of the decision must be given to the applicant and, if the decision was made by a delegate, the decision is a reviewable decision for section 26.

Subsection 17(2) prescribes the applicable clinical assessment fee of $3,970. This fee has been determined through an activity-based costing model, which has been developed to align with the principles outlined in the Australian Government Charging Framework. This fee has also been updated from the previous clinical assessment fee of $4,090 which was specified in the Previous Rules.

The fee associated with this assessment type is charged to recover the costs of obtaining a clinical assessment from a clinical expert with relevant expertise as part of the assessment by the Expert Clinical Advisory Groups (ECAGs) and the Medical Device and Human Tissue Advisory Committee (MDHTAC). The clinical assessment fee is charged per medical device.

**Section 18 ­ Economic assessment fee**

Section 18 outlines circumstances in which an economic assessment is required and the fee for that assessment. Paragraph 72-15(2)(c) of the Act enables the MDHTP Rules to specify the circumstances in which a cost-recovery fee is charged.

Subsection 18(1) prescribes when an economic assessment is required for a listing or variation application relating to a medical device. An economic assessment is required in circumstances where expert advice from an expert with health economics expertise is necessary, or, under subsection 18(1)(b), where the Minister is satisfied on “any other grounds” that the application for a listing or variation requires an economic assessment.

Examples of “any other grounds” that may satisfy the Minister or delegate that an application requires an economic assessment are:

* if the sponsor submits a variation application, or
* if the sponsor resubmits an application, which was assessed at the time of the initial assessment and compliance with the listing criteria was established, but expert clinical advice is required to determine whether ARTG entry and/or MBS items stated in the application are correct.

The first note under subsection 18(1) clarifies that the listing criteria for Parts A and C of the Prescribed List referred to in paragraph 18(1)(a) relate to whether the medical device was compared to medical devices listed in the Prescribed List or alternative treatments, and the medical device is no less clinical effective than alternative devices or treatments and the benefit amount is proportionate to the clinical effectiveness of the device.

The second note under subsection 18(1) clarifies that the listing criteria for Part D of the Prescribed List referred to in paragraph 18(1)(a) relate to whether the medical device was compared to medical devices listed in the Prescribed List, and the medical device is no less clinical effective than alternative devices and the benefit amount is proportionate to the clinical effectiveness of the device.

The third note under subsection 18(1)(a) draws to readers’ attention that where the Minister (including a delegate) is satisfied that the application requires an economic assessment, notice of the decision must be given to the applicant and, if the decision was made by a delegate, the decision is a reviewable decision for section 26.

Economic assessment occurs where expert advice is required to determine whether the benefit amount proposed for the device is proportionate to the clinical effectiveness of the device. The fee associated with this assessment type is charged to recover the costs of obtaining an economic assessment, the development of a focused commentary (or appraisal) of the economic claims made in the application, and for the assessment performed by the MDHTAC. The economic assessment fee is charged per medical device.

Subsection 18(2) prescribes the following three applicable economic assessment fee types:

1. a simple fee of $9,250;
2. a complex fee of $17,680; and
3. an other fee of $28,920.

These fees have been determined through an activity-based costing model, which has been developed to align with the principles outlined in the Australian Government Charging Framework. They have also been updated from the fees specified in the Previous Rules, which were $8,940 for the simple fee, $17,080 for the complex fee and $27,940 for any other fee.

Subsection 18(3) specifies that the simple economic assessment fee applies to a listing and variation application requiring economic assessment to establish cost-effectiveness for a single device with a single purpose.

This fee includes the development of a commentary (or appraisal) of the economic claims and providing a critique on information supplied by the applicant, and for the evaluation performed by the ECAGs and MDHTAC.

Subsection 18(4) specifies that the complex economic assessment fee applies to a listing and variation application requiring economic assessment to establish cost-effectiveness for a single device to which multiple clinical purposes are attributed, or for ‘related’ devices.

This fee includes the development of a commentary (or appraisal) of the economic claims and providing a critique on information supplied by the applicant, and for the evaluation performed by the ECAGs and MDHTAC.

Subsection 18(5) specifies that the other economic assessment fee applies to applications requiring the preparation of ‘fit-for-purpose’ cost-effectiveness advice that extends beyond a critique of the information supplied by the applicant, and for the evaluation performed by the ECAGs and MDHTAC.

**Section 19 ­ Full health technology assessment pathway fee**

Section 19 outlines circumstances in which a full health technology assessment is required and the fee for that assessment. Paragraph 72-15(2)(c) of the Act enables the MDHTP Rules to specify the circumstances in which a cost-recovery fee is charged.

Subsection 19(1) provides that a listing or variation application relating to a medical device requires a full health technology assessment if subsection 19(2) applies, or, under subsection 19(1)(b), if the Minister is satisfied on ‘any other grounds’ that a health technology assessment is required.

Examples of ‘any other grounds’ that may satisfy the Minister or delegate that a full health technology assessment is required are:

* if the sponsor submits a variation application, or
* if the sponsor resubmits an application, which was assessed at the time of the initial assessment and compliance with the listing criteria was established, but expert clinical advice is required to determine whether ARTG entry and/or MBS items stated in the application are correct.

The note to subsection 19(1) clarifies for readers that where the Minister (including a delegate) is satisfied that the application requires a full health technology assessment, notice of the decision must be given to the applicant and, if the decision was made by a delegated, the decision is a reviewable decision for section 26.

Subsection 19(2) applies if the applicant has not paid both a clinical assessment fee and an economic assessment fee in relation to an application, and the application is, or will be, subject to a request to the Medical Services Advisory Committee (MSAC) for any of the following:

1. to establish a Medicare Benefits Schedule (MBS) item in relation to a medical service involving the medical device;
2. to amend an existing MBS item to cover a medical service involving the medical device; or
3. to provide advice about the cost effectiveness or clinical effectiveness of the medical device.

If the applicant has already incurred both the clinical and economic assessment fee in relation to their application at the point it is established that MSAC services are required, the full health technology assessment fee will not be payable. This ensures that the applicant is not required to pay a duplicate fee for an application that has already undergone assessment and administration in relation to the Prescribed List.

Services provided under this pathway are required when a full and comprehensive health technology assessment is required to establish comparative safety, clinical effectiveness, cost-effectiveness and total cost of the medical device and related medical service. In such cases there may be financial impacts to the health system more broadly than just the Prescribed List.

As the full health technology assessment is performed by MSAC, this fee recovers only the activities performed in establishing eligibility for listing; correctness of the grouping; appropriateness of the information provided in the application; and final advice considered by the ECAGs and MDHTAC directly in relation to listing the medical device product on the Prescribed List.

Subsection 19(3) prescribes the full health technology assessment pathway fee of $2,990. This fee has been determined through an activity-based costing model, which has been developed to align with the principles outlined in the Australian Government Charging Framework. This fee has also been updated from the previous full health technology assessment pathway fee of $3,300 which was specified in the Previous Rules. The full health technology assessment pathway fee is charged per medical device.

**Division 2—Payment of cost-recovery fees**

**Section 20 ­ When cost-recovery fee must be paid**

Subsection 20(1) provides the section that specifies the timing for when cost-recovery fees become due and payable for the purposes of paragraph 72-30 of the Act.

Notes to this subsection indicate that the Minister:

* may not list a medical device product in the Schedule until all relevant cost-recovery fees are paid; and
* may remove the medical device from the Schedule should the applicant fail to pay the relevant cost-recovery fees.

Notes to the subsection also indicate that the Commonwealth:

* may not carry out activities on assessment of the medical device application until relevant cost-recovery fees are paid at the time they are due and payable; and
* may commence debt-recovery activities in relation to any unpaid cost-recovery fees.

Subsection 20(2) provides that the standard application fee for listing is due and payable within 28 days from the day demand for payment of the relevant fee is made.

Subsection 20(3) provides that the standard application fee for a variation is due and payable within 28 days from the day demand for payment of the relevant fee is made.

Subsection 20(4) provides that a clinical assessment fee, economic assessment fee, or full health technology pathway fee are due and payable within 28 days from the day a demand for payment of the relevant fee is made.

**Section 21 Person liable to pay cost-recovery fee**

Section 21 provides that the person liable to pay the related cost-recovery fee is the person who made the relevant listing application or variation application.

**Division 3—Refunds and waiver of cost-recovery fees**

**Section 22 ­ Refunds**

Subsection 22(1) provides that this section is made for the purposes of paragraph 72-45(d) of the Act and specifies the circumstances in which the Minister, or delegate, may refund relevant cost-recovery fees.

Subsection 22(2) provides that subject to subsections 22(3) and 22(4), a cost-recovery fee is not refundable in any circumstance, including where:

* the applicant chooses to withdraw the listing or variation application;
* the Minister decides not to grant the listing application; or
* the Minister decides not to grant a variation application.

In relation to the withdrawal of applications, both listing and variation applications are to be submitted through the Health Products Portal (HPP). Processing of an application occurs as soon as possible following receipt of payment. In circumstances where a submission is made through the HPP and no payment is received, no processing of the application will commence.

In relation to listing applications that are not successful in obtaining the relevant listing, this provision outlines that the applicant is still liable to pay fees incurred for the services that have been provided for the assessment of their application.

In relation to variation applications that are not successful in obtaining the relevant variation, this provision outlines that the applicant is still liable to pay fees incurred for the services that have been provided for the assessment of their application.

Subsection 22(3) provides that in the circumstance where the person making the application pays more than what is required, the Department must refund an amount equal to the amount that was overpaid.

This will ensure that where a waiver or an exceptional circumstance exists and the applicant has paid fees that are not required to be paid, the applicant is assured of a refund equal to that which was overpaid. For example, this provision will apply where an applicant is eligible to receive a waiver for all services but has paid all cost-recovery fees prior to the waiver being granted. In such a case, the Department will refund the full amount that was waived.

Subsection 22(4) provides that if the Minister is satisfied that exceptional circumstances exist, the whole, or part of the cost-recovery fee that has been paid may be refunded.

This provision is intended to provide applicants with refunds in specific circumstances which the Minister or delegate may determine are appropriate to provide a refund. Without limitation, the Minister may be satisfied for subsection 24(4) that “exceptional circumstances” exist where an error in the administration of the application has a material impact on the listing or requires the applicant to remake the application, such as:

* overpayment because of a fee waiver deemed eligible post payment of cost recovery fees;
* overpayment because of a request to review certain decisions related to cost recovery fees; or
* an administrative or system error, which resulted in the generation of an invoice and payment of that invoice by the applicant, where the relevant service was not provided.

Refunds under subsection 22(4) may be at the Minister’s own initiative, or on written application by the applicant, meaning applicants can put forward other grounds for consideration by the Minister or delegate.

Subsection 22(5) provides the Minister or delegate with the discretionary power to issue a refund for a reviewable decision, following receipt of a written application from the relevant applicant. This provision is intended to allow the applicant to receive a refund where a reviewable decision, for example such as whether the application in question is eligible for a cost-recovery fee waiver, has been made, and the applicant has successfully obtained a favourable review in which the Minister or delegate determines that the relevant fees should be waived.

The first note under subsection 22(5) provides that where the Minister (including a delegate) makes refuses a request for a refund of the whole or part of a cost-recovery fee, notice must be given to the applicant and, where the decision was made by a delegate, the decision is a reviewable decision for section 26.

The second note under subsection 22(5) refers the reader to section 77 of the *Public Governance, Performance and Accountability Act 2013* which provides the appropriation for refunds under section 22.

**Section 23 ­ Waiver of cost-recovery fees**

Subsection 23(1) provides that this section is made for the purposes of paragraph 72-15(2)(e) of the Act and specifies the circumstances in which the Minister, or delegate, may waive relevant cost-recovery fees.

Waivers have been incorporated to provide for circumstances where it is inappropriate to charge cost-recovery fees and to ensure that applications that are likely to be financially unviable but will still provide benefit to the Australian public, will continue to be submitted to the Department for consideration.

Subsection 23(2) provides that a waiver of some of the clinical assessment fees or the economic assessment fees may be applicable for listing or variation applications (the relevant application) that relates to a medical device if:

* one or more than one, listing or variation applications (the ‘other applications’) are made in addition to the relevant application; and
* the relevant application and the other applications are made specifically in relation for the assessment of related devices; and
* in relation to the clinical assessment fee, the Minister is satisfied that:
	+ a single clinical assessment or one or more abridged clinical assessments can be conducted for the related medical devices, and
	+ the fee for at least one clinical assessment has not otherwise been waived; and
* in relation to the economic assessment fee, the Minister is satisfied that:
	+ a single economic assessment or one or more abridged economic assessments can be conducted for the related medical devices, and
	+ the fee for one economic assessment has not otherwise been waived; and
* the applicant requested the waiver at the time of making an application; and
* the applicant provided reasons why the clinical assessment fee or the economic assessment fee should not apply to their application.

Medical devices are ***related*** if the main equipment and the accessory and ancillary medical devices are designed to be utilised together for an expected clinical outcome. Related medical devices are covered under the same product material (product brochure, surgical technique, instructions for use, etc) and the clinical data for these devices is provided under the same report from the same source (clinical trial, registry, etc) and this information allows the assessment of all devices together. The device requires the submission of more than one application (an application for each component of the system) resulting in the incurrence of multiple cost-recovery fees.

As these related medical devices may be assessed together, some applications may be subjected to the same or abridged clinical and/or economic assessment(s). As such, the Minister or delegate may determine that one or more of the payable clinical and/or economic assessment fee(s) could be waived. This subsection provides applicants who are required to submit multiple applications to list all the respective components of the related devices on the Prescribed List, an option to request a waiver of each of the duplicative cost-recovery fees.

The first note under subsection 23(2) indicates that applications referred to in the subsection may not be the only listing or variation applications made by the person.

The second note under subsection 23(2) refers the reader to the section 5, which defines the circumstances for when medical devices are ***related***.

The third note under subsection 23(2) indicates for readers that where the Minister (including a delegate) decides to refuse to a request for the waiver of a cost-recovery fee, notice must be given to the applicant for the refund and where the decision was made by a delegate, the decision is a reviewable decision for section 26.

**Division 4—Review**

**Section 24 ­ Reviewable decisions**

Section 24 outlines that the following decisions made by the Minister, or delegate, are subject to internal review (are reviewable):

* that an application requires clinical assessment on any grounds other than those specified in the listing criteria.
* that an application requires economic assessment on any grounds other than those specified in the listing criteria.
* that an application requires a full health technology assessment on any grounds other than requests for MSAC advice to include or amend an MBS item, or where advice on cost-effectiveness or clinical-effectiveness is sought.
* that exceptional circumstances do not exist to justify the refund of either the whole or part of a cost-recovery fee.
* that cost-recovery fee(s) should not be waived for applications made for related devices on the grounds that fewer or abridged clinical and/or economic assessment may be conducted on some of the relevant applications.

The note to this section clarifies that the decision of the Minister could be made by a delegate of the Minister.

**Section 25 ­ Notice of review rights**

Subsection 25(1) provides that in the event that a reviewable decision is made, the Minister must notify the applicant of the decision in writing within 10 business days of making the decision. Written notice of the decision must be accompanied by a statement of the applicant’s rights to review.

Subsection 25(2) provides that the written notice must provide instructions on how the applicant may respond to the notice for the purpose of requesting a review of the decision.

Under subsection 25(3), reviewable decisions remain valid in circumstances where the Minister does not provide written notice of the decision along with the applicants review rights within 10 days business days of making the decision.

**Section 26 ­ Internal review of decisions made by delegates**

Subsection 26(1) permits an applicant to request to the Minister, in writing, an internal review of a reviewable decision that has been made under Part 4 during the assessment process.

This provision provides applicants who are dissatisfied with a decision with the means to dispute and request review of discretionary decisions made throughout the course of the application assessment process. As reviewable decisions have a direct impact on determining the total amount payable in relation to cost-recovery fees and the use of the review process may alter the total amount payable by the applicant.

**The internal review will be undertaken by a different person with appropriate delegation (not the same person who made the original decision). Should a further review be requested (second internal review), a different third delegate would review the original decision.**

The internal review provisions rely on the necessary and convenient power in paragraph 333-20(1)(b) of the Act.

The purpose of the internal review is to provide applicants with the means to request reconsideration of the circumstances informing the outcome of a reviewable decision. It provides applicants with the opportunity to submit additional relevant information (justification) to inform either the level of assessment necessary on their application, or the circumstances that enhance their eligibility to qualify for a waiver. Each stage of the internal review will be conducted fairly by appropriate delegates of the Minister that have not been involved in making the reviewable decision, or if required, have not been involved in making the subsequent internal review decision.

The utilisation of an internal review process allows for the fair and efficient resolution of disputed reviewable decisions. The efficient resolution of all disputes in relation to the payable cost-recovery fees are of high importance to ensure that the application in dispute may still have sufficient time and resources allocated to the assessment to be able to obtain an outcome from the MDHTAC, and if recommended, timely inclusion on the Prescribed List. This ensures that applicants will not be delayed in accessing the public market, and the Australian public will continue to access new medical devices and human tissue products without delay. The internal review process aligns that process which is also in place for similar committees that also conduct a Health Technology Assessment review.

The significant volume of highly technical applications requires the Department to efficiently manage all resources allocated and contracted to assess applications within each assessment cycle. It was considered that there was a significant risk to the efficient provision of services if an external process, (requiring dedicated Departmental resources to facilitate) was implemented. An external process was judged likely to adversely impact other applicants (those who make applications within the same cycle) due to the disruption to services, and the likely need to continue to allocate resources to the application in dispute. Such external processes were considered likely to have extensive timelines, and likely to significantly delay access to market for the applicant, and access to the product for consumers.

Subsection 26(2) provides that the application seeking a review of a reviewable decision must be made within 10 business days (or longer if approved by the Minister) of receipt of the written notice of the decision. The application must also include the reasons for requesting review of the decision.

Subsection 26(3) provides that within 10 business days of receipt of a written application, the Minister or a delegate of the Minister must review the reviewable decision, and determine whether to affirm or vary the decision, or revoke the decision and make any other decision that is appropriate. The applicant must be notified in writing of the outcome of the ‘initial review decision’ within that period.

Subsection 26(4) provides that an applicant may subsequently apply to review the reviewable decision by making an application in writing to the Minister within 10 days of receipt of the outcome to the initial review decision.

Subsection 26(5) provides that within 10 days of receipt of a written application to review the initial review decision, the Minister or a delegate of the Minister, who differs from the previous decision maker (further reviewer), must review the initial review decision. The Minister or the delegate must determine whether to affirm or vary the initial review decision, or to revoke the initial review decision. The applicant must be notified of the outcome of the further review decision within that period.

Subsections 26(6) and (7) provides limitations to the operation of subsections 26(3) and (5) respectively as it relates to a delegate making an initial review decision and a further review decision. Subsection 26(6) provides that a delegate must not review a reviewable decision under subsection (3) if that delegate was involved in making the reviewable decision. Similarly, subsection 26(7) provides that a delegate must not review an initial review decision under subsection (5) if the delegate was involved in making either the initial review decision or the reviewable decision that relates to the initial review decision.

The reference to a ‘delegate’ under section 26 refers to a delegate of the Minister who is an SES officer, or acting SES officer in the Department.

Whilst decisions under Part 4 can be subject to internal review, they are not subject to independent merits review. Independent merits review is not available because the Administrative Review Tribunal’s (ART) jurisdiction to review administrative decisions (section 12 of the *Administrative Review Tribunal Act 2024* (ART Act)) is only enlivened if an Act or a legislative instrument provides for an application to be made to the ART for review of the decision.

The MDHTP Rulesare made under item 4 of the Table in paragraph 333‑20 of the *Private Health Insurance Act 2007* (PHI Act), which permits the Minister to make Rules for the purposes of Part 3-3 of the PHI Act (requirements for complying health insurance products). Paragraph 328-5 of the PHI Act lists the decisions under the Act that are reviewable by the ART, which do not include any decisions under the MDHTP Rules.

**Section 27 ­ Notice of overpayment as a result of a review decision**

Section 27 provides that if an applicant is found to have overpaid their cost-recovery fees as a result of either an initial review decision or a further review decision, the Minister must within 20 business days of the decision being made notify the applicant of the overpayment and refund the amount equal to the amount overpaid.

**Part 5 ­ Miscellaneous**

**Section 28 ­ Minister may have regard to recommendations and advice**

Section 28 provides that, in making a decision under section 72-10 of the Act, the Minister may have regard to a recommendation or advice from the MDHTAC when deciding whether or not to grant the application to list a kind of medical device or human tissue product.

The MDHTAC provides recommendations and advice to the Minister for Health and Aged Care and the Department about the listing of products on the Prescribed List and the benefits payable by private health insurers. This section is made for the purposes of paragraph 333-20(1)(b) of the Act, which provides for the MDHTP Rules to deal with matters that are necessary or convenient to be provided for in order to carry out or give effect to Part 3-3 of the Act.

**Schedule 1 – Prescribed List**

Schedule 1 lists the kinds of medical devices and human tissue products and contains the ‘minimum benefit’ and conditions for provision of the kinds of medical devices and human tissue products for private and public hospital treatment, and hospital-substitute treatment. Schedule 1 is to be known as the Prescribed List of Benefits for Medical Devices and Human Tissue Products (Prescribed List).

**Schedule 2 – Repeals**

Schedule 2 sets out the instrument repealed by the MDHTP Rules.

**ATTACHMENT B**

**Statement of Compatibility with Human Rights**

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011*

***Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024***This instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of the Legislative Instrument**

The Table in subsection 72-1(2) (the Table) of Part 3-3 of the *Private Health Insurance* *Act 2007* (the Act) provides for benefit requirements a complying health insurance policy that covers hospital treatment must meet. Under item 4 of the Table, there must be a benefit for the provision of a medical device or human tissue product, of a kind listed in the Private Health Insurance (Medical Devices and Human Tissue Products) Rules, in specified circumstances and under any specified conditions. The specified circumstances are that the listed item is provided in circumstances in which a medicare benefit is payable or in other circumstances which may be set out in the Private Health Insurance (Medical Devices and Human Tissue Products) Rules. The specified conditions are any that may be set out in the Private Health Insurance (Medical Devices and Human Tissue Products) Rules.

The purpose of the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2024* (MDHTP Rules) is to remake the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024* (Previous Rules)to update the prescribed list of the kinds of medical devices and human tissue products for which a benefit must be paid, where the listed item is provided in the conditions and circumstances specified in the Act. The MDHTP Rules set out the minimum benefit payable for each listed item.

Listed items and their minimum benefits are set out in Schedule 1 to the MDHTP Rules. Schedule 1 to the MDHTP Rules is known as the Prescribed List of Benefits for Medical Devices and Human Tissue Products (Prescribed List).

The MDHTP Rules also outline circumstances in which various assessments in relation to listing and variation applications are required and the associated fee for that assessment, and cost-recovery provisions, including the timing for when cost-recovery fees become due and payable, and when cost-recovery fees can be refunded and waivers can be granted.

The MDHTP Rules differ from the *Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2024* by:

* adding 192 new listed items (billing codes) to Part A of the Prescribed List as a result of listing medical devices following successful new applications, 10 billing codes as the result of expansion applications, 2 billing codes as the result of compression applications and 222 new billing codes due to transfer of billing codes from one sponsor to another;
* changing the listing details of 127 billing codes in Part A of the Prescribed List following the successful amendment applications from the sponsors, and changes to groupings for billing codes listed incorrectly;
* deleting 415 billing codes from Part A of the Prescribed List, as a result of accepting 183 deletion applications submitted by the sponsors, removing 222 billing codes after transferring billing codes to the new sponsors, removing 4 billing codes following completion of expansion applications and removing 6 billing codes following completion of compression applications;
* adding 8 new billing codes in Part C of the Prescribed List as a result of listing medical devices following successful new applications;
* deleting 8 billing codes following acceptance of deletion applications;
* adding 60 new billing codes in Part D as a result of listing medical devices following 55 successful new applications, 2 new billing codes as the result of successful expansion applications and 3 new billing codes due to transfer of billing codes from one sponsor to another;
* Changes to 7 billing codes in Part D following the successful amendment applications; and
* deleting 32 billing codes from Part D following deletion applications and decision to remove the billing codes for medicines and accessories to medicines from the Prescribed List.

The numbers of Prescribed List billing codes were taken from reports produced by the Health Products Portal (HPP) when the list was run.

Pre-July 2024, the structure for Part A, Part C, and Part D billing codes was a two-digit alpha prefix to denote the sponsor and a three-digit number to identify the device, and for Part B billing codes were a three-digit alpha prefix to denote the sponsor and a two-digit number to identify the human tissue product. Due to the number of sponsors of medical devices listed on the PL, the number of two-digit alpha prefixes has been exhausted. From 1 July 2024 all new billing codes are presented as a six-digit number only and are allocated to the new billing codes sequentially.

In addition to the new and amended billing codes change, the MDHTP Rules also differ from the Previous Rules by correcting the listing details of billing codes that were identified as being listed in incorrect groupings (meaning category-subcategory-group-subgroup-suffix); that is, the devices do not have the attributes to fit in the groupings, they are currently listed in.

When Prescribed List billing codes are transferred from one sponsor to a different sponsor, or billing codes are compressed or expanded following the respective application, the Prescribed List billing codes that are transferred, expanded, or compressed are deleted.

The MDHTP Rules also differ from the Previous Rules by omitting the provision that defined ‘medical device’, which widened the scope of the meaning set out at paragraph 72-11(1)(b) of the Act.

Section 11 of the MDHTP Rules, which sets out the general listing criteria, has also been updated to provide that a medical device or human tissue product must not be listed in the Prescribed List unless it is included as a medical device or biological in the Australian Register of Therapeutic Goods maintained under section 9A of the *Therapeutic Goods Act 1989*.

**Human rights implications**

The MDHTP Rules engage article 12 of the International Covenant on Economic Social and Cultural Rights (ICESCR), specifically the right to health.

*Right to Health*

The right to the enjoyment of the highest attainable standard of physical and mental health is contained in article 12(1) of the ICESCR. Whilst the UN Committee on Economic Social and Cultural Rights has stated that the right to health is not to be understood as a right to be healthy, it does entail a right to a system of health protection which provides equality of opportunity for people to enjoy the highest attainable level of health. In addition, the right to health must meet certain key requirements, including that health care must be scientifically and medically appropriate and of good quality.

*Analysis*

The addition of new items in the Prescribed List will increase the amount of choice an insured person can have in relation to the kind of medical device or human tissue product for which they must receive a minimum private health insurance benefit.  This will impact positively on the right to health of insured persons.

The MDHTP Rules also remove entries at the request of the sponsors of these devices or products. The sponsors of these devices or products are no longer supplying these devices or products for use to privately insured persons in Australia.

Generally, the devices and products removed from the MDHTP Rules have been replaced by newer models due to upgraded technologies or advancements in surgical procedures, or are still available for privately insured patients, but are supplied by different sponsors.

The MDHTP Rules will also continue listing medical devices in Part D and provide listing criteria for these devices. This will ensure that devices that have historically been included in Part D of Schedule 1 to the Previous Rules will continue to be listed, and patients will continue to access these devices.

**Conclusion**

The MDHTP Rules is compatible with human rights because it enables advances in the protection of human rights, in particular the right to health.

**Andrew Rintoul**

**Assistant Secretary**

**Prescribed List Reform Taskforce**

**Technology Assessment and Access Division**

**Health Resourcing Group**

**Department of Health****and Aged Care**